Investigative Radiology:使用BOLD成像模型实现心肌组织氧合及微血管血容量的无创测量

2022-09-10 shaosai MedSci原创

血氧水平依赖性信号是由Ogawa等学者首次报道的,已经彻底改变了脑功能成像的流程及格局。

现阶段血管磁共振成像(MRI)已被广泛用于评估心肌的宏观结构和微观结构,许多研究已经证明了绘制心肌参数图的临床价值。另一种评估重要血液动力学变化的方法是使用血氧水平依赖性(BOLD)对比。血氧水平依赖性信号是由Ogawa等学者首次报道的,已经彻底改变了脑功能成像的流程及格局

有研究表明狭窄的冠状动脉远端微血管处于血管扩张的基础状态,并可能在糖尿病、非缺血性扩张型心肌病、冠状动脉狭窄、心脏移植排斥和淀粉样变疾病状态下受到影响。研究表明微血管血容量(MBVs)的测量是一项重要的组织特征。

最早的心肌BOLD研究是在动物呼吸和孤立的灌注心脏模型中进行的。在一份评估心肌BOLD信号生理基础的早期手稿中,Atalay证明了在孤立的灌注兔心脏恒定血流条件下,T2和血液中血红蛋白氧饱和度之间的强烈相关性。在后来的研究中,人类志愿者的心肌BOLD信号在基线和由多巴胺或双嘧达莫诱导的心肌应激过程中被显示出来

近日,发表在Investigative Radiology杂志的一项研究提出了一个可以定量测量药物诱导的微血管容积变化的BOLD MRI模型,并使用BOLD MRI测量了药物诱导的组织氧合变化,为早期识别心肌的微观病理变化、实现早期干预及治疗提供了技术支持。

本研究使用了12只健康大鼠进行研究。在输注增加微血管血流的腺苷或增加心肌耗氧量的多巴胺的情况R2*maps。此外,在静脉注射单晶氧化铁纳米粒子后,注射及不注射腺苷或多巴胺的情况下R2*maps。 

结果显示,使用腺苷时,微血管总体积增加了10.8%,使用多巴胺时增加了25.6%(P<0.05)。当比较心内膜与心外膜时,腺苷和多巴胺都显示心内膜和心外膜的MBV变化有明显差异(P < 0.05)。腺苷的心肌总氧饱和度增加了6.59%,多巴胺增加了1.64%(P = 0.27)。每种药物的心外膜和心内膜氧饱和度变化的差异都很明显(腺苷P < 0.05,多巴胺P < 0.05)。 


 大鼠心肌的R2*maps。A,静状态。B,腺苷输注期间。C,单晶铁氧化颗粒(MION)给药后,未注射腺苷。D,使用MION后,并注射腺苷

本研究结果证明了使用校准的血氧水平依赖性MRI来量化微血管容积和氧合变化的能力,并证明了腺苷和多巴胺使用下的不同反应。本研究提出的方法在检查各种疾病状态下的微血管疾病方面具有较大的临床潜力,且无需使用任何放射性药物或钆基造影剂,安全性及实用性进一步得到提升。

原文出处:

Jeffrey M Dendy,Sean G Hughes,Jonathan H Soslow,et al.Myocardial Tissue Oxygenation and Microvascular Blood Volume Measurement Using a Contrast Blood Oxygenation Level-Dependent Imaging Model.DOI:10.1097/RLI.0000000000000871

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051851, encodeId=df44205185158, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 26 20:41:32 CST 2023, time=2023-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040990, encodeId=a2792040990f1, content=<a href='/topic/show?id=c37089010f7' target=_blank style='color:#2F92EE;'>#血容量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89010, encryptionId=c37089010f7, topicName=血容量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat May 27 08:41:32 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365452, encodeId=3b1b1365452a4, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504003, encodeId=70be150400300, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051851, encodeId=df44205185158, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 26 20:41:32 CST 2023, time=2023-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040990, encodeId=a2792040990f1, content=<a href='/topic/show?id=c37089010f7' target=_blank style='color:#2F92EE;'>#血容量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89010, encryptionId=c37089010f7, topicName=血容量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat May 27 08:41:32 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365452, encodeId=3b1b1365452a4, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504003, encodeId=70be150400300, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051851, encodeId=df44205185158, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 26 20:41:32 CST 2023, time=2023-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040990, encodeId=a2792040990f1, content=<a href='/topic/show?id=c37089010f7' target=_blank style='color:#2F92EE;'>#血容量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89010, encryptionId=c37089010f7, topicName=血容量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat May 27 08:41:32 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365452, encodeId=3b1b1365452a4, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504003, encodeId=70be150400300, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-09-11 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051851, encodeId=df44205185158, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 26 20:41:32 CST 2023, time=2023-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2040990, encodeId=a2792040990f1, content=<a href='/topic/show?id=c37089010f7' target=_blank style='color:#2F92EE;'>#血容量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89010, encryptionId=c37089010f7, topicName=血容量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sat May 27 08:41:32 CST 2023, time=2023-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365452, encodeId=3b1b1365452a4, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1504003, encodeId=70be150400300, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Sep 11 08:41:32 CST 2022, time=2022-09-11, status=1, ipAttribution=)]
    2022-09-11 yibei

相关资讯

NeuroImage:戴口罩对fMRI BOLD的影响

佩戴口罩进行梯度回波功能磁共振成像可以改变BOLD基线信号,但对任务激活的影响很小。

Radiology:BOLD功能磁共振成像在胶质瘤恶性程度评估中的应用

脑胶质瘤的进展通过新生血管、血管生成、神经血管单元的重塑和异常代谢物的产生破坏了局部脑血管系统的结构和功能的完整性,最终会改变胶质瘤的血管微环境。

Radiology:BOLD功能磁共振成像在烟雾病中的应用

评估脑组织缺血性风险是脑血管疾病诊断的一项基本任务。目前临床上可通过使用CT、MRI或SPECT监测脑组织血流量,以达到检测脑缺血的目的。

Eur Radiol:用BOLD MRI来看看胎儿肺发育情况!

BOLD技术可用于评估胎儿肺功能受损程度,为将来在病理条件下的研究铺平了道路。

Euro Radio:静息状态的fMRI机器学习预测PRC皮层肿瘤患者的个体化手部运动

准确的脑功能区映射在术前规划中起着至关重要的作用,不仅有助于评估手术风险和疗效,还有助于避免手术引起的神经功能缺损。血氧水平依赖(BOLD)功能磁共振成像(fMRI)是一种无创成像技术,越来越多地应用

Radiology:静息态功能MRI在胶质瘤患者神经血管解偶联中的应用

静息态功能MRI是一种允许在患者休息时生成功能性MRI数据的影像学技术。